Innovative Strategies to Boost the Immunogenicity of Cancer Vaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 20 March 2026 | Viewed by 11
Special Issue Editors
Interests: cancer biology; cancer immunotherapies
Special Issue Information
Dear Colleagues,
Cancer vaccines hold great promise in immuno-oncology, yet their clinical efficacy has often been limited by the low immunogenicity of tumor antigens and the challenge of immune tolerance. This Special Issue highlights recent advances in developing and optimizing cancer vaccines, including subunit protein, peptide-based, mRNA, and viral vector platforms, to elicit potent and durable anti-tumor immune responses. We welcome contributions on novel antigen design, delivery technologies, and adjuvant systems that enhance antigen uptake, processing, and presentation. Particular emphasis will be placed on strategies that upregulate MHC class I and II expression, expand epitope coverage, and overcome HLA restriction as well as tumor antigen heterogeneity. We also invite studies exploring the combination of cancer vaccines with other modalities, such as immune checkpoint inhibitors, cytokine therapies, adoptive T cell transfer, antibody–drug conjugates (ADCs), and T cell engagers, to synergistically improve therapeutic efficacy. This Special Issue aims to showcase state-of-the-art innovations driving the next generation of cancer vaccines toward meaningful clinical impacts.
Prof. Dr. Eric O'Neill
Dr. Shisong Jiang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer vaccines
- tumor antigens
- tumor-associated antigens (TAAs)
- tumor-specific antigens (TSAs)
- subunit vaccines
- peptide vaccines
- mRNA vaccines
- viral vector vaccines
- adjuvants
- antigen presentation
- MHC class I and II upregulation
- cancer immunotherapy
- antibody–drug conjugates (ADCs)
- T cell engages
- combination immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
